WO2001076574A2 - Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists - Google Patents

Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists Download PDF

Info

Publication number
WO2001076574A2
WO2001076574A2 PCT/EP2001/004116 EP0104116W WO0176574A2 WO 2001076574 A2 WO2001076574 A2 WO 2001076574A2 EP 0104116 W EP0104116 W EP 0104116W WO 0176574 A2 WO0176574 A2 WO 0176574A2
Authority
WO
WIPO (PCT)
Prior art keywords
hypertension
renal failure
pharmaceutically acceptable
acceptable salt
restenosis
Prior art date
Application number
PCT/EP2001/004116
Other languages
French (fr)
Other versions
WO2001076574A3 (en
Inventor
Ronald Edward Steele
Original Assignee
Novartis Ag
Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020027013486A priority Critical patent/KR20020089437A/en
Priority to AU7393801A priority patent/AU7393801A/en
Application filed by Novartis Ag, Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. filed Critical Novartis Ag
Priority to HU0301335A priority patent/HUP0301335A3/en
Priority to AU2001273938A priority patent/AU2001273938B2/en
Priority to SK1461-2002A priority patent/SK14612002A3/en
Priority to KR1020027013874A priority patent/KR100755768B1/en
Priority to BR0110079-3A priority patent/BR0110079A/en
Priority to MXPA02010091A priority patent/MXPA02010091A/en
Priority to PL01358459A priority patent/PL358459A1/en
Priority to JP2001574092A priority patent/JP2003530343A/en
Priority to NZ521855A priority patent/NZ521855A/en
Priority to EP01940317A priority patent/EP1282410A2/en
Priority to IL15208101A priority patent/IL152081A0/en
Priority to CA002405895A priority patent/CA2405895A1/en
Publication of WO2001076574A2 publication Critical patent/WO2001076574A2/en
Publication of WO2001076574A3 publication Critical patent/WO2001076574A3/en
Priority to NO20024920A priority patent/NO20024920L/en
Priority to US11/291,008 priority patent/US20060122217A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising
  • the invention furthermore relates to a method for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
  • Atherosclerosis atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
  • the present invention relates to a method of prevention of, delay of progression of or treatment of endothelial dysfunction with or without hypertension comprising administering to a warm-blooded animal, including man, in need thereof an effective amount of an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof.
  • ATi-receptor antagonists also called angiotensin II receptor antagonists
  • angiotensin II receptor antagonists are understood to be those active ingredients which bind to the AT V receptor subtype of angiotensin II receptor but do not result in activation of the receptor.
  • these antagonists can, for example, be employed as antihypertensives or for treating congestive heart failure.
  • the class of ATi receptor antagonists comprises compounds having differing structural features, essentially preferred are the non-peptidic ones.
  • Preferred ATt-receptor antagonist are those agents which have been marketed, most preferred is valsartan or a pharmaceutically acceptable salt thereof.
  • a diuretic is, for example, a thiazide derivative selected from the group consisting of chlorothiazide, hydrochlorothiazide, methylclothiazide, and chlorothalidon. The most preferred is hydrochlorothiazide.
  • Aldosterone synthase inhibitor is an enzyme which converts corticosterone to aldosterone to by hydroxylating cortocosterone to form 18-OH-corticosterone and 18-OH-corticosterone to aldosterone.
  • the class of aldosterone synthase inhibitors know to be applied for the treatment of hypertension and primary aldosteronism comprises both steroidal and non- steroidal aldosterone synthase inhibitors, the later being most preferred.
  • the class of aldosterone synthase inhibitors comprises compounds having differing structural features.
  • the most preferred non-steroidal aldosterone synthase inhibitor is the (+)-enantiomer of the hydrochloride of fadrozole (US patents 4617307 and 4889861) of formula
  • compositions according to the present invention can be used for the prevention of, the delay of progression of and treatment of a disease or condition selected from the group consisting of
  • Atherosclerosis atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
  • CAO coronary artery occlusion
  • (+)-enantioner of the hydrochloride of fadrozole Alza osmotic minipumps 0.4 mg/kg/d.
  • cardiomyocytes cross-sectional area and length in sections of LV myocardium
  • Infarct size Six ⁇ m-thick transverse histological sections of the left ventricle are stained with nitroblue tetrazolium and acquired by a B/W XC-77CE CCD video camera (Sony). The resulting image is processed on a KS 300 image analysis system (Carl Zeiss Vision) using a software specifically developed (Porzio et al., 1995). A single operator blinded to treatment interactively defines the boundaries of the interventricular septum, and the infarcted area on each section is semiautomatically identified as the area of unstained ventricular tissue. The software automatically calculates for each component of the ventricular section defined as the chamber, septum, infarcted area, infarcted LV wall and viable LV wall, a set of geometric parameters (Porzio et al., 1995).
  • Hearts are fixed in situ, by retrograde perfusion with buffered 4% formaldehyde after arrest in diastole by i.v. injection of 0.5 M KCI. After fixation, the left ventricle (LV) and the free wall of the right ventricle are separately weighed; LV longer diameter is measured with a caliper.
  • LV histological sections are stained with hematoxylin & eosin for qualitative examination and to quantify cardiomyocytes cross-sectional area with a semi-automated image analysis routine. Interstitial collagen deposition in LV is evaluated on Sirius red stained sections with a semi-automated image analysis routine (Masson et al., 1998).
  • Collagen content in LV spared myocardium LV tissue in the spared myocardium is homogenized, subjected to PAGE-SDS electrophoresis and electroblotted onto nitrocellulose membrane. The blots are exposed to primary antibodies, i.e. rabbit anti-rat collagen type I or type III antiserum (Chemicon). The primary antibodies are recognized by secondary antibodies conjugated to alkaline phosphatase (for collagen type I) or peroxidase (collagen type III).
  • LV chamber volume is determined in hearts arrested in diastole (KCI) and fixed in formalin under a hydrostatic pressure equivalent to the measured LV end-diastolic pressure.
  • a metric rod is inserted into the LV to measure LV inner length.
  • the transverse diameters of the LV chamber are measured in two 1 -mm thick transverse sections near to the base and the apex of the ventricle (Jeremic et al., 1996).
  • the chamber volume is computed from an equation integrating transverse diameters and ineer length.
  • a microtip pressure transducer (Millar SPC-320) connected to a recorder (Windograf, Gould Electronics) is inserted into the right carotid artery to record systolic and diastolic blood pressures.
  • the pressure transducer is advanced into the LV to measure LV systolic (LVSP) and end-diastolic (LVEDP) pressures, the first derivative of LV pressure over time (+dP/dt) and heart rate.
  • LVSP LV systolic
  • LEDP end-diastolic
  • Non-invasive blood pressure Systolic blood pressure and heart rate are measured by the tail-cuff method (Letica LE 5002) in conscious rats.
  • Urine electrolytes, hormones Rats are individually housed in metabolic cages and 24-h urine collected on 1 ml HCI 6N. Water intake is measured. Urine catecholamines are extracted on Bondelut C-
  • Plasma and urine aldosterone, and plasma angiotensin II is determined with specific radioimmunoassays (Aldoctk-2, DiaSorin and Angiotensin II, Nichols Diagnostics). Urine sodium and potassium are measured by f lamme photometry.
  • composition of the present invention can be used for the prevention of, delay of progression of, and treatment of survival post myocardial infarction (Ml).
  • Endothelial dysfunction is being acknowledged as a critical factor in vascular diseases.
  • the endothelium plays a bimodal role as the source of various hormones or by-products with opposing effects: vasodilation and vasoconstriction, inhibition or promotion of growth, fibrinolysis or thrombogenesis, production of anti-oxidants or oxidising agents.
  • Genetically predisposed hypertensive animals with endothelial dysfunction constitute a valid model for assessing the efficacy of a cardiovascular therapy.
  • Endothelial dysfunction is characterized by, for example, increased oxidative stress, causing decreased nitric oxide, increased factors involved in coagulation or fibrinolysis such as plasminogen activating inhibitor-1 (PAI-1 ), tissue factor (TF), tissue plasminogen activator (tPA), increased adhesion molecules such as ICAM and VCAM, increased growth factors such as bFGF, TGF ⁇ , PDGF, VEGF, all factors causing cell growth, inflammation and fibrosis.
  • PAI-1 plasminogen activating inhibitor-1
  • TF tissue factor
  • tPA tissue plasminogen activator
  • increased adhesion molecules such as ICAM and VCAM
  • growth factors such as bFGF, TGF ⁇ , PDGF, VEGF, all factors causing cell growth, inflammation and fibrosis.
  • the treatment e.g. of endothelial dysfunction can be demonstrated in the following pharmacological test:
  • the drugs are administered in drinking fluid.
  • the pressor effect of Ang II at 1 mg/kg obtained in controls normotensive rats is reducted by 49 % and 73 % after treatment with valsartan 5 and 50 mg/kg/d , respectively (Gervais et al. 1999).
  • the response to Ang I injected in Wistar Kyoto rats pretreated with the (+)-enantiomer of the hydrochloride of fadrozole or valsartan 5 mg/kg/d is similar.
  • Body weight is measured every week.
  • Systolic blood pressure and heart rate are recorded by tail cuff plethysmography 3 and 2 weeks before starting the study and at 2 weeks after drug administration.
  • Urine is collected over a 24 hour period from rats kept in individual (metabolic) cages the week before starting treatment and at weeks 4 and 12 for volume measurement and protein, creatinine, sodium and potassium determination using standard laboratory methods.
  • blood samples are withdrawn from the retro- orbital plexus (maximum 1 ml) for creatinine, Na + and K * assays.
  • compositions of the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.
  • compositions of the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.
  • composition according to the present invention can be used for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
  • Atherosclerosis atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
  • compositions of the present invention can also be used for the prevention and delay of progression and preferably the treatment of other diseases.
  • a preferred composition comprises the combination of the (+)-enantiomer of the hydrochloride of fadrozole and valsartan or valsartan combined with hydrochlorothiazide.
  • the jointly therapeutically effective amounts of an AT receptor antagonist or of an ATi-receptor antagonist combined with a diuretic, in each case, in free or pharmaceutically acceptable salt form and an aldosterone synthase inhibitor in free or pharmaceutically acceptable salt form can be administered simultaneously or sequentially in any order, separately or in a fixed combination.
  • the invention relates to a method of the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
  • Atherosclerosis atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
  • endothelial dysfunction with or without hypertension comprising administering to a warm-blooded animal, including man, a therapeutically effective amount of an aldosterone synthase inhibitor in free or pharmaceutically acceptable salt form either alone or in combination with an AT receptor antagonist or in combination with an ATrreceptor antagonist combined with a diuretic, in each case, in free or pharmaceutically acceptable salt form.
  • the invention relates to the use of a
  • an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of ( ⁇ ) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
  • ⁇ atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and ( ⁇ ) endothelial dysfunction with or without hypertension.
  • the present invention likewise relates to a "kit-of-parts", for example, in the sense that the components to be combined according to the present invention can be dosed independently or by use of different fixed combinations with distinguished amounts of the components, i.e. simultaneously or at different time points.
  • the parts of the kit of parts can then e.g. be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts.
  • the time intervals are chosen such that the effect on the treated disease or condition in the combined use of the parts is larger than the effect that would be obtained by use of only any one of the components.
  • the invention furthermore relates to a commercial package comprising the combination according to the present invention together with instructions for simultaneous, separate or sequential use.
  • These pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances.
  • the pharmaceutical preparations consist of from about 0.1 % to 90 %, preferably of from about 1 % to about 80 %, of the active compound.
  • Pharmaceutical preparations for enteral or parenteral, and also for ocular, administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner which is known per se, for example using conventional mixing, granulation, coating, solubulizing or lyophilizing processes.
  • compositions for oral use can be obtained by combining the active compound with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.
  • the dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.
  • Preferred dosages for the active ingredients of the pharmaceutical combination according to the present invention are therapeutically effective dosages, especially those which are commerically available.
  • an approximate daily dose of from about 1 mg to about 360 mg is to be estimated e.g. for a patient of approximately 75 kg in weight.
  • the dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.
  • Valsartan as a representative of the class of ATrreceptor antagonists, will be supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 20 to about 320 mg, of valsartan which may be applied to patients.
  • the application of the active ingredient may occur up to three times a day, starting e.g. with a daily dose of 20 mg or 40 mg of valsartan, increasing via 80 mg daily and further to 160 mg daily up to 320 mg daily.
  • valsartan is applied twice a day with a dose of 80 mg or 160 mg, respectively, each. Corresponding doses may be taken, for example, in the morning, at mid-day or in the evening.
  • the film-coated tablet is manufactured e.g. as follows:
  • a mixture of valsartan, microcrystalline cellulose, crospovidone, part of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200, silicon dioxide and magnesium stearate is premixed in a diffusion mixer and then sieve through a screnning mill.
  • the resulting mixture is again pre-mixed in a diffusion mixer, compacted in a roller compacter and then sieve through a screening mill.
  • the rest of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200 are added and the final blend is made in a diffusion mixer.
  • the whole mixture is compressed in a rotary tabletting machine and the tabletts are coated with a film by using Diolack pale red in a perforated pan.
  • Formulation Example 2 Film-coated tablets:
  • the film-coated tablet is manufactured e.g. as described in Formulation Example 1.
  • Iron oxide, black (C.I. No. 77499, E 172) 0.50
  • Iron oxide, brown (C.I. No. 77499, E 172 0.50
  • Iron oxide, red (Cl. No. 77491 , E 172) 0.50
  • Titanium dioxide (Cl. No. 77891 , E 171) 14.00
  • the film-coated tablet is manufactured e.g. as described in Formulation Example 1.
  • the tablet is manufactured e.g. as follows: Granulation/Drying
  • Valsartan and microcrystallin cellulose are spray-granulated in a fluidised bed granulator with a granulating solution consisting of povidone and sodium lauryl sulphate dissolved in purified water.
  • the granulate obtained is dried in a fluidised bed dryer.
  • the dried granulate is milled together with crospovidone and magnesium stearate.
  • the mass is then blended in a conical srew type mixer for approximately 10 minutes.
  • the empty hard gelatin capsules are filled with the blended bulk granules under controlled temperature and humidity conditions.
  • the filed capsules are dedusted, visually inspected, weightchecked and guarantied until by Quality assurance department.
  • a hard gelatin capsule comprising as active ingredient e.g. (S)-N-(1 -carboxy-2-methylprop- 1-yl)-N-pentanoyl-N-[2'(1 H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine, can be formulated, for example, as follows:
  • Components (1 ) and (2) are granulated with a solution of components (3) and (4) in water.
  • the components (5) and (6) are added to the dry granulate and the mixture is filled into size 1 hard gelatin capsules.
  • Formulation Example 8 :

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with (ii) an AT1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.

Description

Combination of Organic Compounds
The invention relates to a pharmaceutical composition comprising
(i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof alone or in combination with,
(ii) an ATVreceptor antagonist or an ATi receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof and
(iii) a pharmaceutically acceptable carrier.
The invention furthermore relates to a method for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
(a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
(c) endothelial dysfunction with or without hypertension, comprising administering the pharmaceutical composition of the present invention.
In a preferred embodiment the present invention relates to a method of prevention of, delay of progression of or treatment of endothelial dysfunction with or without hypertension comprising administering to a warm-blooded animal, including man, in need thereof an effective amount of an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof.
ATi-receptor antagonists (also called angiotensin II receptor antagonists) are understood to be those active ingredients which bind to the ATVreceptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the inhibition of the ATi receptor, these antagonists can, for example, be employed as antihypertensives or for treating congestive heart failure.
The class of ATi receptor antagonists comprises compounds having differing structural features, essentially preferred are the non-peptidic ones. For example, mention may be made of the compounds which are selected from the group consisting of valsartan, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, the compound with the designation E-1477 of the following formula
Figure imgf000003_0001
the compound with the designation SC-52458 of the following formula
Figure imgf000003_0002
and the compound with the designation the compound ZD-8731 of the following formula
Figure imgf000004_0001
or, in each case, a pharmaceutically acceptable salt thereof.
Preferred ATt-receptor antagonist are those agents which have been marketed, most preferred is valsartan or a pharmaceutically acceptable salt thereof.
A diuretic is, for example, a thiazide derivative selected from the group consisting of chlorothiazide, hydrochlorothiazide, methylclothiazide, and chlorothalidon. The most preferred is hydrochlorothiazide.
Aldosterone synthase inhibitor is an enzyme which converts corticosterone to aldosterone to by hydroxylating cortocosterone to form 18-OH-corticosterone and 18-OH-corticosterone to aldosterone. The class of aldosterone synthase inhibitors know to be applied for the treatment of hypertension and primary aldosteronism comprises both steroidal and non- steroidal aldosterone synthase inhibitors, the later being most preferred.
Preference is given to commercially available aldosterone synthase inhibitors or those aldosterone synthase inhibitors that have been approved by the health authorities.
The class of aldosterone synthase inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds which are selected from the group consisting of the non-steroidal aromatase inhibitors anastrozole, fadrozole (including the (+)-enantiomer thereof), as well as the steroidal aromatase inhibitor exemestane, or, in each case where applicable, a pharmaceutically acceptable salt thereof. The most preferred non-steroidal aldosterone synthase inhibitor is the (+)-enantiomer of the hydrochloride of fadrozole (US patents 4617307 and 4889861) of formula
Figure imgf000005_0001
Surprisingly, the pharmaceutical compositions according the present invention exhibit a beneficial, especially a synergistic (= more than additive), therapeutic effect, furthermore benefits resulting from combined treatment such as a surprising prolongation of efficacy, a broader variety of therapeutic treatment and surprising beneficial effects on diseases and conditions associated with ATi-receptors or aldosterone synthase inhibitors, respectively.
The compositions according to the present invention can be used for the prevention of, the delay of progression of and treatment of a disease or condition selected from the group consisting of
(a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
(c) endothelial dysfunction with or without hypertension.
The person skilled in the pertinent art is fully enabled to select a relevant animal test model to prove the hereinbefore and hereinafter indicated therapeutic indications and beneficial effects. These beneficial effects can, for example, be demonstrated in the test model as disclosed by G. Jeremic et al. in J. Cardovasc. Pharmacol. 27:347-354, 1996.
Study design
In the study to be performed, permanent coronary artery occlusion (CAO) in rats is used as a model of acute myocardial infarction. The experiments are carried out with 5 treatment groups characterized by following features:
• sham-operated animals
• CAO + vehicle
• CAO + valsartan
• CAO + aldosterone synthase inhibitor
• CAO + ATi-receptor antagonist + aldosterone synthase inhibitor.
Following doses and routes of administration can be applied: For example for the AT^receptor antagonist valsartan a) -3d to +2d: s.c. injections 2.5 mg/kg BW/12 h b) +3d to +28d: s.c. Alza osmotic minipumps 5 mg/kg/d
For the (+)-enantioner of the hydrochloride of fadrozole Alza osmotic minipumps 0.4 mg/kg/d.
During the study following variables are measured:
• infarct size
• LV chamber volume
• interstitial and perivascular collagen density in spared LV myocardium
• COL-I and COL-HI protein content in spared LV myocardium by Western blot
• cardiomyocytes cross-sectional area and length in sections of LV myocardium
• plasma concentrations of Ang II and aldosterone
• urine concentration of sodium, potassium and aldosterone
• blood pressure in conscious animals
• LV and carotid blood pressure in anesthetized animals.
Methodology
Infarct size: Six μm-thick transverse histological sections of the left ventricle are stained with nitroblue tetrazolium and acquired by a B/W XC-77CE CCD video camera (Sony). The resulting image is processed on a KS 300 image analysis system (Carl Zeiss Vision) using a software specifically developed (Porzio et al., 1995). A single operator blinded to treatment interactively defines the boundaries of the interventricular septum, and the infarcted area on each section is semiautomatically identified as the area of unstained ventricular tissue. The software automatically calculates for each component of the ventricular section defined as the chamber, septum, infarcted area, infarcted LV wall and viable LV wall, a set of geometric parameters (Porzio et al., 1995).
Histology: Hearts are fixed in situ, by retrograde perfusion with buffered 4% formaldehyde after arrest in diastole by i.v. injection of 0.5 M KCI. After fixation, the left ventricle (LV) and the free wall of the right ventricle are separately weighed; LV longer diameter is measured with a caliper. LV histological sections are stained with hematoxylin & eosin for qualitative examination and to quantify cardiomyocytes cross-sectional area with a semi-automated image analysis routine. Interstitial collagen deposition in LV is evaluated on Sirius red stained sections with a semi-automated image analysis routine (Masson et al., 1998).
Collagen content in LV spared myocardium: LV tissue in the spared myocardium is homogenized, subjected to PAGE-SDS electrophoresis and electroblotted onto nitrocellulose membrane. The blots are exposed to primary antibodies, i.e. rabbit anti-rat collagen type I or type III antiserum (Chemicon). The primary antibodies are recognized by secondary antibodies conjugated to alkaline phosphatase (for collagen type I) or peroxidase (collagen type III).
Left ventricular chamber volume: LV chamber volume is determined in hearts arrested in diastole (KCI) and fixed in formalin under a hydrostatic pressure equivalent to the measured LV end-diastolic pressure. A metric rod is inserted into the LV to measure LV inner length. The transverse diameters of the LV chamber are measured in two 1 -mm thick transverse sections near to the base and the apex of the ventricle (Jeremic et al., 1996). The chamber volume is computed from an equation integrating transverse diameters and ineer length.
Systemic and Left ventricular hemodynamics: A microtip pressure transducer (Millar SPC-320) connected to a recorder (Windograf, Gould Electronics) is inserted into the right carotid artery to record systolic and diastolic blood pressures. The pressure transducer is advanced into the LV to measure LV systolic (LVSP) and end-diastolic (LVEDP) pressures, the first derivative of LV pressure over time (+dP/dt) and heart rate. Non-invasive blood pressure: Systolic blood pressure and heart rate are measured by the tail-cuff method (Letica LE 5002) in conscious rats.
Urine electrolytes, hormones: Rats are individually housed in metabolic cages and 24-h urine collected on 1 ml HCI 6N. Water intake is measured. Urine catecholamines are extracted on Bondelut C-|8 columns (Varian), separated by HPLC (Apex-ll C18, 3 μm,
50x4.5 mm analytical column, Jones Chromatography) and quantified with an electrochemical detector (Coulochem II, ESA) (Goldstein etal., 1981). Plasma and urine aldosterone, and plasma angiotensin II is determined with specific radioimmunoassays (Aldoctk-2, DiaSorin and Angiotensin II, Nichols Diagnostics). Urine sodium and potassium are measured by f lamme photometry.
Sample size
10 animals analyzable in each treatment groups are sufficient to detect biologically significant differences. Only rats with an infarct size of at least 10% of the LV section area are included in the final analysis.
Accordingly, the composition of the present invention can be used for the prevention of, delay of progression of, and treatment of survival post myocardial infarction (Ml).
Endothelial dysfunction is being acknowledged as a critical factor in vascular diseases. The endothelium plays a bimodal role as the source of various hormones or by-products with opposing effects: vasodilation and vasoconstriction, inhibition or promotion of growth, fibrinolysis or thrombogenesis, production of anti-oxidants or oxidising agents. Genetically predisposed hypertensive animals with endothelial dysfunction constitute a valid model for assessing the efficacy of a cardiovascular therapy.
Endothelial dysfunction is characterized by, for example, increased oxidative stress, causing decreased nitric oxide, increased factors involved in coagulation or fibrinolysis such as plasminogen activating inhibitor-1 (PAI-1 ), tissue factor (TF), tissue plasminogen activator (tPA), increased adhesion molecules such as ICAM and VCAM, increased growth factors such as bFGF, TGFβ, PDGF, VEGF, all factors causing cell growth, inflammation and fibrosis. The treatment e.g. of endothelial dysfunction can be demonstrated in the following pharmacological test:
Material and methods
Male 20-24 week-old SHR, purchased from RCC Ldt (Fullingsdorf, Switzerland), are maintained in a temperature- and light-controlled room with free access to rat chow (Nafag 9331 , Gossau, Switzerland) and tap water. The experiment is performed in accordance with the NIH guidelines and approved by the Canton Veterinary office (Bew 161 , Kantonales Veterinaramt, Liestal, Switzerland). All rats are treated with the NO synthase inhibitor L-NAME (Sigma Chemicals) administered in drinking water (50 mg/l) for 12 weeks. The average daily dose of L-NAME calculated from the water consumed was 2.5 mg/kg/d (range 2.1-2.7 ).
The rats are divided into 5 groups: group 1 , control (n = 40); Group 2, valsartan (5 mg/kg/d; n = 40); Group 3, the (+)-enantiomer of the hydrochloride of fadrozole (n = 30); Group 4, a combination of the (+)-enantiomer of the hydrochloride of fadrozole and valsartan (5 mg/kg/d); n = 30) and Group 5, valsartan (50 mg/kg/d; n = 30). The drugs are administered in drinking fluid. The pressor effect of Ang II at 1 mg/kg obtained in controls normotensive rats is reducted by 49 % and 73 % after treatment with valsartan 5 and 50 mg/kg/d , respectively (Gervais et al. 1999). The response to Ang I injected in Wistar Kyoto rats pretreated with the (+)-enantiomer of the hydrochloride of fadrozole or valsartan 5 mg/kg/d is similar.
Body weight is measured every week. Systolic blood pressure and heart rate are recorded by tail cuff plethysmography 3 and 2 weeks before starting the study and at 2 weeks after drug administration. Urine is collected over a 24 hour period from rats kept in individual (metabolic) cages the week before starting treatment and at weeks 4 and 12 for volume measurement and protein, creatinine, sodium and potassium determination using standard laboratory methods. At the same time points, blood samples are withdrawn from the retro- orbital plexus (maximum 1 ml) for creatinine, Na+ and K* assays.
Ten rats from each group are sacrificed at 4 weeks for collection of kidney and heart for moφhological analysis. The remaining rats are sacrificed at 12 weeks. Cardiac and kidney weight is recorded. Terminal blood sampling is performed in 5 % EDTA at 4 (moφhometry study) and 12 (end of the study) weeks for aldosterone, determination by radioimmunoassay using a DPC coat-a-count aldosterone-RIA kit (Bϋhlmann, Switzerland).
Statistical analysis:
All data are expressed as mean ± SEM. Statistical analysis is performed using a one-way ANOVA, followed by a Duncan's multiple range test and a Newman-Keuls test, for comparison between the different groups. Results with a probability value of less than 0.05 are deemed statistically significant.
An improvement of regression of atherosclerosis without effecting the serum lipid levels can, for exmple, be demonstrated by using the animal model as disclosed by H. Kano et al. in Biochemical and Biophysical Research Communications 259, 414-419 (1999).
That the compounds or combinations according to the present invention can be used for the regression of a cholesterol diet-induced atherosclerosis, can be demonstrated using the test model described, e.g., by C. Jiang et al. in Br. J. Pharmacol. (1991), 104, 1033-1037.
That the compounds or compositions according to the present invention can be used for the treatment of renal failure, especially chronic renal failure, can be demonstrated using the test model described, e.g., by D. Cohen et al. in Journal of Cardiovascular Pharmacology, 32: 87-95 (1998).
Further benefits when applying the composition of the present invention are that lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.
All the more suφrising is the experimental finding that the combined administration of combination according to the present invention results in a beneficial, especially a synergistic, therapeutic effect, but also in benefits resulting from the combined treatment and further surprising beneficial effects compared to a monotherapy applying only one of the pharmaceutically active compounds used in the combinations disclosed herein.
In particular, all the more suφrising is the experimental finding that the combination of the present invention results in a beneficial, especially a synergistic, therapeutic effect but also in benefits resulting from combined treatment such as a surprising prolongation of efficacy, a broader variety of therapeutic treatment and surprising beneficial effects on diseases and conditions as specified hereinbefore or hereinafter.
Further benefits when applying the composition of the present invention are that lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.
The results of the studies clearly show that the composition according to the present invention can be used for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
(a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
(c) endothelial dysfunction with or without hypertension.
The compositions of the present invention can also be used for the prevention and delay of progression and preferably the treatment of other diseases. A preferred composition comprises the combination of the (+)-enantiomer of the hydrochloride of fadrozole and valsartan or valsartan combined with hydrochlorothiazide.
Preferably, the jointly therapeutically effective amounts of an AT receptor antagonist or of an ATi-receptor antagonist combined with a diuretic, in each case, in free or pharmaceutically acceptable salt form and an aldosterone synthase inhibitor in free or pharmaceutically acceptable salt form can be administered simultaneously or sequentially in any order, separately or in a fixed combination.
Furthermore, the invention relates to a method of the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
(a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
(c) endothelial dysfunction with or without hypertension; comprising administering to a warm-blooded animal, including man, a therapeutically effective amount of an aldosterone synthase inhibitor in free or pharmaceutically acceptable salt form either alone or in combination with an AT receptor antagonist or in combination with an ATrreceptor antagonist combined with a diuretic, in each case, in free or pharmaceutically acceptable salt form.
Furthermore, the invention relates to the use of a
(a) pharmaceutical composition comprising
(i) an ATrreceptor antagonist or an AT receptor antagonist combined with a diuretic, or, in each case, a pharmaceutically acceptable salt thereof,
(ii) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable earner; or
(b) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of (α) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(β) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and (χ) endothelial dysfunction with or without hypertension.
The present invention likewise relates to a "kit-of-parts", for example, in the sense that the components to be combined according to the present invention can be dosed independently or by use of different fixed combinations with distinguished amounts of the components, i.e. simultaneously or at different time points. The parts of the kit of parts can then e.g. be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. Preferably, the time intervals are chosen such that the effect on the treated disease or condition in the combined use of the parts is larger than the effect that would be obtained by use of only any one of the components.
The invention furthermore relates to a commercial package comprising the combination according to the present invention together with instructions for simultaneous, separate or sequential use.
These pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances. For example, the pharmaceutical preparations consist of from about 0.1 % to 90 %, preferably of from about 1 % to about 80 %, of the active compound. Pharmaceutical preparations for enteral or parenteral, and also for ocular, administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner which is known per se, for example using conventional mixing, granulation, coating, solubulizing or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compound with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.
The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.
Preferred dosages for the active ingredients of the pharmaceutical combination according to the present invention are therapeutically effective dosages, especially those which are commerically available.
Normally, in the case of oral administration, an approximate daily dose of from about 1 mg to about 360 mg is to be estimated e.g. for a patient of approximately 75 kg in weight.
The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.
Valsartan, as a representative of the class of ATrreceptor antagonists, will be supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 20 to about 320 mg, of valsartan which may be applied to patients. The application of the active ingredient may occur up to three times a day, starting e.g. with a daily dose of 20 mg or 40 mg of valsartan, increasing via 80 mg daily and further to 160 mg daily up to 320 mg daily. Preferably, valsartan is applied twice a day with a dose of 80 mg or 160 mg, respectively, each. Corresponding doses may be taken, for example, in the morning, at mid-day or in the evening.
The following examples illustrate the above-described invention; however, it is not intended to restrict the scope of this invention in any manner. Formulation Example 1 : Film-Coated Tablets:
Figure imgf000015_0001
Removed during processing.
The film-coated tablet is manufactured e.g. as follows:
A mixture of valsartan, microcrystalline cellulose, crospovidone, part of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200, silicon dioxide and magnesium stearate is premixed in a diffusion mixer and then sieve through a screnning mill. The resulting mixture is again pre-mixed in a diffusion mixer, compacted in a roller compacter and then sieve through a screening mill. To the resulting mixture, the rest of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200 are added and the final blend is made in a diffusion mixer. The whole mixture is compressed in a rotary tabletting machine and the tabletts are coated with a film by using Diolack pale red in a perforated pan. Formulation Example 2: Film-coated tablets:
Figure imgf000016_0001
The film-coated tablet is manufactured e.g. as described in Formulation Example 1.
Formulation Example 3: Film-Coated Tablets:
Figure imgf000017_0001
*' The composition of the Opadry® brown OOF16711 coloring agent is tabulated below. M) Removed during processing Opadry® Composition:
Iron oxide, black (C.I. No. 77499, E 172) 0.50
Iron oxide, brown (C.I. No. 77499, E 172 0.50
Iron oxide, red (Cl. No. 77491 , E 172) 0.50
Iron oxide, yellow (Cl. No. 77492, E 172) 0.50
Macrogolum (Ph. Eur) 4.00
Titanium dioxide (Cl. No. 77891 , E 171) 14.00
Hypromellose (Ph. Eur) 80.00
The film-coated tablet is manufactured e.g. as described in Formulation Example 1.
Formulation Example 4: Capsules:
Valsartan [= active ingredient] 80.00
Microcrystalline cellulose 25.10
Crospovidone 13.00
Povidone 12.50
Magnesium stearate 1.30
Sodium lauryl sulphate 0.60
Iron oxide, red 0.123
(Cl. No. 77491 , EC No. E 172)
Iron oxide, yellow 0.123
(C.I. No. 77492, EC No. E 172)
Iron oxide, black 0.245
(Cl. No. 77499, EC No. E 172)
Titanium dioxide 1.540
Gelatin 74.969
The tablet is manufactured e.g. as follows: Granulation/Drying
Valsartan and microcrystallin cellulose are spray-granulated in a fluidised bed granulator with a granulating solution consisting of povidone and sodium lauryl sulphate dissolved in purified water. The granulate obtained is dried in a fluidised bed dryer.
Milling/Blending
The dried granulate is milled together with crospovidone and magnesium stearate. The mass is then blended in a conical srew type mixer for approximately 10 minutes.
Encapsulation
The empty hard gelatin capsules are filled with the blended bulk granules under controlled temperature and humidity conditions. The filed capsules are dedusted, visually inspected, weightchecked and guarantied until by Quality assurance department.
Formulation Example 5: Capsules:
Figure imgf000019_0001
The formulation is manufactured e.g. as described in Formulation Example 4. Formulation Example 6: Hard Gelatine Capsule:
■i£ '22% fϋnWs ff iW fnfg)',
Valsartan [= active ingredient] 80.00
Sodium laurylsulphate 0.60
Magnesium stearate 1.30
Povidone 12.50
Crospovidone 13.00
Microcrystalline cellulose 21.10
Formulation Example 7:
A hard gelatin capsule, comprising as active ingredient e.g. (S)-N-(1 -carboxy-2-methylprop- 1-yl)-N-pentanoyl-N-[2'(1 H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine, can be formulated, for example, as follows:
Composition:
(1 ) valsartan 80.0 mg
(2) microcrystalline cellulose 110.0 mg
(3) polyvidone K30 45.2 mg
(4) sodium lauryl sulfate 1.2 mg
(5) crospovidone 26.0 mg
(6) magnesium stearate 2.6 mg
Components (1 ) and (2) are granulated with a solution of components (3) and (4) in water. The components (5) and (6) are added to the dry granulate and the mixture is filled into size 1 hard gelatin capsules. Formulation Example 8:
Figure imgf000021_0001
1) 1.035 mg CGS 16 949 A hemihydrate is equivalent to 1.000 mg anhydrate.

Claims

What is claimed is
1. Use of a pharmaceutical composition comprising
(i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof alone or in combination with,
(ii) an ATrreceptor antagonist or an ATi receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof and
(iii) a pharmaceutically acceptable carrier; for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
(a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
(c) endothelial dysfunction with or without hypertension.
2. Use according to claim 1 wherein said ATi-receptor antagonist is selected from the group consisting of valsartan, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, the compound with the designation E-1477 of the following formula
Figure imgf000022_0001
the compound with the designation SC-52458 of the following formula
Figure imgf000023_0001
and the compound with the designation the compound ZD-8731 of the following formula
Figure imgf000023_0002
or, in each case, a pharmaceutically acceptable salt thereof.
3. Use according to claim 2 wherein said AT receptor antagonist is valsartan or a pharmaceutically acceptable salt thereof.
4. Use according to any one of claims claims 1 to 3 wherein said aldosterone synthase inhibitor is selected from the group consisting of anastrozole, fadrozole (including the (+)- enantiomer thereof, and exemestane, or, in each case where applicable, a pharmaceutically acceptable salt thereof.
5. Use according to any one of claims 1 to 4 wherein said aldosterone synthase inhibitor is (+)-enantiomer of the hydrochloride of fadrozole of formula
Figure imgf000024_0001
6. Use according to any one of claims 1 to 5 wherein the diuretic is hydrochlorothiazide.
7. Use of a pharmaceutical composition comprising an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
(α) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(β) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
(χ) endothelial dysfunction with or without hypertension.
8. A pharmaceutical composition comprising:
(i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with,
(ii) an ATi-receptor antagonist or an ATi receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof; and
(iii) a pharmaceutically acceptable carrier; for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of (a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
(c) endothelial dysfunction with or without hypertension.
9. A method for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
(a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
(b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
(c) endothelial dysfunction with or without hypertension; comprising administering to a warm-blooded animal, including man, a therapeutically effective amount of an aldosterone synthase inhibitor in free or pharmaceutically acceptable salt form.
10. Method according to claim 9 further comprising administering a therapeutically effective amount of an ATi-receptor antagonist or an ATi receptor antagonist combined with a diuretic, in each case, in free or pharmaceutically acceptable salt form.
PCT/EP2001/004116 2000-04-12 2001-04-10 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists WO2001076574A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IL15208101A IL152081A0 (en) 2000-04-12 2001-04-10 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
MXPA02010091A MXPA02010091A (en) 2000-04-12 2001-04-10 Combination of organic compounds.
HU0301335A HUP0301335A3 (en) 2000-04-12 2001-04-10 Combination of organic compounds
AU2001273938A AU2001273938B2 (en) 2000-04-12 2001-04-10 Novel medical use of aldosterone synthase inhibitors alone or in combination with ati-receptor antagonists
SK1461-2002A SK14612002A3 (en) 2000-04-12 2001-04-10 Novel medical use of aldosterone synthase inhibitors alone or in combination with AT1-receptor antagonists
KR1020027013874A KR100755768B1 (en) 2000-04-19 2001-04-10 Methylation of indole compounds using dimethyl carbonate
BR0110079-3A BR0110079A (en) 2000-04-12 2001-04-10 Combination of organic compounds
KR1020027013486A KR20020089437A (en) 2000-04-12 2001-04-10 Combination of organic compounds
PL01358459A PL358459A1 (en) 2000-04-12 2001-04-10 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
NZ521855A NZ521855A (en) 2000-04-12 2001-04-10 Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a dirruretic to treat various conditions
JP2001574092A JP2003530343A (en) 2000-04-12 2001-04-10 Novel pharmaceutical use of aldosterone synthase inhibitor alone or in combination with AT1-receptor antagonist
EP01940317A EP1282410A2 (en) 2000-04-12 2001-04-10 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
AU7393801A AU7393801A (en) 2000-04-12 2001-04-10 Combination of organic compounds
CA002405895A CA2405895A1 (en) 2000-04-12 2001-04-10 Combination of organic compounds
NO20024920A NO20024920L (en) 2000-04-12 2002-10-11 Combination of organic compounds
US11/291,008 US20060122217A1 (en) 2000-04-12 2005-11-30 Combination of organic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19674200P 2000-04-12 2000-04-12
US60/196,742 2000-04-12

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/149,107 A-371-Of-International US20030083342A1 (en) 2000-04-12 2001-04-10 Combination of organic compounds
US10/826,106 Division US20040204444A1 (en) 2000-04-12 2004-04-15 Combination of organic compounds
US10/940,544 Continuation US20050059697A1 (en) 2000-04-12 2004-09-14 Combination of organic compounds

Publications (2)

Publication Number Publication Date
WO2001076574A2 true WO2001076574A2 (en) 2001-10-18
WO2001076574A3 WO2001076574A3 (en) 2002-04-25

Family

ID=22726655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004116 WO2001076574A2 (en) 2000-04-12 2001-04-10 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists

Country Status (19)

Country Link
EP (1) EP1282410A2 (en)
JP (1) JP2003530343A (en)
KR (1) KR20020089437A (en)
CN (1) CN1422152A (en)
AR (1) AR032316A1 (en)
AU (2) AU7393801A (en)
BR (1) BR0110079A (en)
CA (1) CA2405895A1 (en)
HU (1) HUP0301335A3 (en)
IL (1) IL152081A0 (en)
MX (1) MXPA02010091A (en)
NO (1) NO20024920L (en)
NZ (1) NZ521855A (en)
PE (1) PE20020082A1 (en)
PL (1) PL358459A1 (en)
RU (1) RU2002129569A (en)
SK (1) SK14612002A3 (en)
WO (1) WO2001076574A2 (en)
ZA (1) ZA200208204B (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009683A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
WO2004060399A1 (en) * 2002-12-27 2004-07-22 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
WO2004087136A1 (en) * 2003-04-03 2004-10-14 Astrazeneca Ab Use of atii antagonist for the treatment or prevention of metabolic syndrome
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
WO2006048736A1 (en) * 2004-11-03 2006-05-11 Universita' Degli Studi Del Piemonte Orientale 'a. Avogadro' Use of a corticosteroid in association with a diuretic and an antacid for the treatment of vascular stenosis and the prevention of vascular restenosis
JP2006515566A (en) * 2002-08-10 2006-06-01 ベセスダ ファーマシューティカルズ， インコーポレイテッド Novel PPAR ligand that does not induce fluid retention, edema or congestive heart failure
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
WO2006066961A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
WO2006128853A1 (en) * 2005-05-31 2006-12-07 Speedel Experimenta Ag Heterocyclic spiro-compounds as aldosterone synthase inhibitors
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
WO2007116099A1 (en) * 2006-04-12 2007-10-18 Speedel Experimenta Ag Imidazo compounds
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
JP2010523465A (en) * 2006-04-12 2010-07-15 シュペーデル・エクスペリメンタ・アーゲー Condensed imidazole derivatives as aromatase inhibitors
EP2239268A1 (en) 2001-05-15 2010-10-13 Novartis AG Dipeptide derivatives
WO2010136493A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
WO2011061271A1 (en) 2009-11-20 2011-05-26 Novartis Ag Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
WO2012065956A1 (en) 2010-11-16 2012-05-24 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors
WO2012065953A1 (en) 2010-11-16 2012-05-24 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as nep inhibitors
WO2013008164A2 (en) 2011-07-08 2013-01-17 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
WO2014081702A2 (en) 2012-11-20 2014-05-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
WO2014126979A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
US8835646B2 (en) 2005-08-25 2014-09-16 Novartis Ag Organic compounds
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015013168A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
EP3048100A1 (en) 2009-05-28 2016-07-27 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
WO2018073788A1 (en) 2016-10-21 2018-04-26 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
WO2019154416A1 (en) 2018-02-07 2019-08-15 Novartis Ag Substituted bisphenyl butanoic ester derivatives as nep inhibitors
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
WO2020110009A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2020110011A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
US10822332B2 (en) 2016-10-27 2020-11-03 Damian Pharma Ag Aldosterone synthase inhibitor
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
WO2023094965A1 (en) 2021-11-23 2023-06-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder
US11992479B2 (en) 2018-05-03 2024-05-28 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252565A (en) * 1990-04-02 1993-10-12 Merrell Dow Pharmaceuticals Inc. Haloethyl-substituted steroid enzyme inhibitors
WO1998003180A2 (en) * 1996-07-22 1998-01-29 The Victoria University Of Manchester Use of sex steroids function modulators to treat wounds and fibrotic disorders
FR2766821A1 (en) * 1997-07-29 1999-02-05 Sanofi Sa 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
WO1999045779A1 (en) * 1998-03-11 1999-09-16 Smithkline Beecham Corporation Novel compositions of eprosartan
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO2000002543A2 (en) * 1998-07-10 2000-01-20 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd New bicyclic condensed imidazole derivative

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252565A (en) * 1990-04-02 1993-10-12 Merrell Dow Pharmaceuticals Inc. Haloethyl-substituted steroid enzyme inhibitors
WO1998003180A2 (en) * 1996-07-22 1998-01-29 The Victoria University Of Manchester Use of sex steroids function modulators to treat wounds and fibrotic disorders
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
FR2766821A1 (en) * 1997-07-29 1999-02-05 Sanofi Sa 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO1999045779A1 (en) * 1998-03-11 1999-09-16 Smithkline Beecham Corporation Novel compositions of eprosartan
WO2000002543A2 (en) * 1998-07-10 2000-01-20 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HAGMANN M ET AL: "SC-52458, an orally active angiotensin II-receptor antagonist: Inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers." JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 29, no. 4, 1997, pages 444-450, XP001053467 ISSN: 0160-2446 *
MAKINO N ET AL: "Regression of Hypertrophy After Myocardial Infarction is Produced by the Chronic Blockade of Angiotensin Type 1 Receptor in Rats" JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, XX, XX, vol. 28, no. 3, 1996, pages 507-517, XP002106098 ISSN: 0022-2828 *
MASATO H ET AL: "ALGAAS/GAAS/INGAAS DOUBLE-DOPED QUANTUM-WELL HEMTS FOR LOW DISTORTION AMPLIFIER" EXTENDED ABSTRACTS OF THE INTERNATIONAL CONFERENCE ON SOLID STATE DEVICES AND MATERIALS, JAPAN SOCIETY OF APPLIED PHYSICS. TOKYO, JA, 29 August 1993 (1993-08-29), pages 715-717, XP000409466 *
MAXFIELD E K ET AL: "Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats." DIABETOLOGIA, vol. 36, no. 12, 1993, pages 1230-1237, XP001053448 ISSN: 0012-186X *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 07, 31 July 1997 (1997-07-31) & JP 09 071586 A (YAMANOUCHI PHARMACEUT CO LTD), 18 March 1997 (1997-03-18) *
S.BUDAVARI EDITOR: "The Merck Index, 12th Edition" , MERCK & CO., INC. , WHITEHOUSE STATION, N.J., U.S.A. XP002178362 page 105, paragraph 667 page 666, paragraph 3969 *
See also references of EP1282410A2 *
VIIGIMAA M ET AL: "Tasosartan and hydroclorothiazide as combination therapy in the treatment of severe essential hypertension: Comparison with enalapril." CARDIOVASCULAR DRUGS AND THERAPY, vol. 14, no. 4, August 2000 (2000-08), pages 447-449, XP001053452 ISSN: 0920-3206 *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009683A3 (en) * 2000-07-27 2003-09-12 Pharmacia Corp Aldosterone blocker therapy to prevent or treat inflammation-related disorders
WO2002009683A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
EP2239268A1 (en) 2001-05-15 2010-10-13 Novartis AG Dipeptide derivatives
JP2006515566A (en) * 2002-08-10 2006-06-01 ベセスダ ファーマシューティカルズ， インコーポレイテッド Novel PPAR ligand that does not induce fluid retention, edema or congestive heart failure
WO2004060399A1 (en) * 2002-12-27 2004-07-22 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
US7582662B2 (en) 2002-12-27 2009-09-01 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
JP2006522115A (en) * 2003-04-03 2006-09-28 アストラゼネカ アクチボラグ Use of ATII antagonists for the treatment or prevention of metabolic syndrome
WO2004087136A1 (en) * 2003-04-03 2004-10-14 Astrazeneca Ab Use of atii antagonist for the treatment or prevention of metabolic syndrome
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
WO2006048736A1 (en) * 2004-11-03 2006-05-11 Universita' Degli Studi Del Piemonte Orientale 'a. Avogadro' Use of a corticosteroid in association with a diuretic and an antacid for the treatment of vascular stenosis and the prevention of vascular restenosis
WO2006066961A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
EA015108B1 (en) * 2004-12-24 2011-06-30 КРКА, д.д., НОВО МЕСТО Process for preparing solid pharmaceutical composition comprising valsartan
EA012392B1 (en) * 2004-12-24 2009-10-30 Крка, Д.Д. Ново Место Solid pharmaceutical composition comprising valsartan
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
WO2006128853A1 (en) * 2005-05-31 2006-12-07 Speedel Experimenta Ag Heterocyclic spiro-compounds as aldosterone synthase inhibitors
US8071773B2 (en) 2005-05-31 2011-12-06 Novartisag Heterocyclic spiro-compounds as aldosterone synthase inhibitors
US8835646B2 (en) 2005-08-25 2014-09-16 Novartis Ag Organic compounds
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
WO2007116099A1 (en) * 2006-04-12 2007-10-18 Speedel Experimenta Ag Imidazo compounds
JP2009533395A (en) * 2006-04-12 2009-09-17 シュペーデル・エクスペリメンタ・アーゲー Imidazo compounds
JP2010523465A (en) * 2006-04-12 2010-07-15 シュペーデル・エクスペリメンタ・アーゲー Condensed imidazole derivatives as aromatase inhibitors
US8138176B2 (en) 2006-04-12 2012-03-20 Novartis Ag Imidazo compounds
US7879847B2 (en) 2006-04-12 2011-02-01 Novartis Ag Imidazo compounds
JP2009534319A (en) * 2006-04-12 2009-09-24 シュペーデル・エクスペリメンタ・アーゲー Imidazo compounds
WO2009106640A2 (en) * 2008-02-28 2009-09-03 Maastricht University N-benzyl imidazole derivatives
WO2009106640A3 (en) * 2008-02-28 2009-10-29 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
WO2010136493A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
EP3048100A1 (en) 2009-05-28 2016-07-27 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
EP2594556A1 (en) 2009-05-28 2013-05-22 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
EP2594557A1 (en) 2009-05-28 2013-05-22 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
WO2011061271A1 (en) 2009-11-20 2011-05-26 Novartis Ag Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
EP2735561A1 (en) 2009-11-20 2014-05-28 Novartis AG Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
WO2012065956A1 (en) 2010-11-16 2012-05-24 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors
WO2012065953A1 (en) 2010-11-16 2012-05-24 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as nep inhibitors
WO2013008164A2 (en) 2011-07-08 2013-01-17 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
WO2014081702A2 (en) 2012-11-20 2014-05-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
WO2014126979A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015013168A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
WO2018073788A1 (en) 2016-10-21 2018-04-26 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
EP4141006A1 (en) 2016-10-21 2023-03-01 Novartis AG Naphthyridinone derivatives and their use in the treatment of arrhythmia
US10822332B2 (en) 2016-10-27 2020-11-03 Damian Pharma Ag Aldosterone synthase inhibitor
US11447491B2 (en) 2016-10-27 2022-09-20 Damian Pharma Ag Aldosterone synthase inhibitor
EP3778557A1 (en) 2018-02-07 2021-02-17 Novartis AG Combinations comprising a substituted biphenylbutanoic ester derivative as nep inhibitor and valsartan
WO2019154416A1 (en) 2018-02-07 2019-08-15 Novartis Ag Substituted bisphenyl butanoic ester derivatives as nep inhibitors
US11992479B2 (en) 2018-05-03 2024-05-28 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism
WO2020110009A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2020110011A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
WO2023094965A1 (en) 2021-11-23 2023-06-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Also Published As

Publication number Publication date
AU7393801A (en) 2001-10-23
NO20024920L (en) 2002-11-27
BR0110079A (en) 2002-12-31
HUP0301335A2 (en) 2003-08-28
MXPA02010091A (en) 2003-02-12
HUP0301335A3 (en) 2006-02-28
SK14612002A3 (en) 2003-05-02
NZ521855A (en) 2004-10-29
CN1422152A (en) 2003-06-04
JP2003530343A (en) 2003-10-14
AR032316A1 (en) 2003-11-05
PL358459A1 (en) 2004-08-09
AU2001273938B2 (en) 2005-03-03
KR20020089437A (en) 2002-11-29
NO20024920D0 (en) 2002-10-11
WO2001076574A3 (en) 2002-04-25
ZA200208204B (en) 2003-10-14
EP1282410A2 (en) 2003-02-12
PE20020082A1 (en) 2002-02-21
RU2002129569A (en) 2004-03-27
IL152081A0 (en) 2003-05-29
CA2405895A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
AU2001273938B2 (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with ati-receptor antagonists
AU2001273938A1 (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with ati-receptor antagonists
EP1341533B1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
US20090036432A1 (en) Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic
US20060122217A1 (en) Combination of organic compounds
NZ534086A (en) Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a diuretic to treat various conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10149107

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001940317

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001273938

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 152081

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 521855

Country of ref document: NZ

Ref document number: 1020027013486

Country of ref document: KR

Ref document number: IN/PCT/2002/1650/CHE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2001 574092

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2405895

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14612002

Country of ref document: SK

Ref document number: PV2002-3380

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002/08204

Country of ref document: ZA

Ref document number: PA/a/2002/010091

Country of ref document: MX

Ref document number: 018079172

Country of ref document: CN

Ref document number: 200208204

Country of ref document: ZA

Ref document number: 02091881

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2002 2002129569

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1200201026

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020027013486

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001940317

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-3380

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 521855

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521855

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001273938

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: PV2002-3380

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001940317

Country of ref document: EP